CEO

Post-MVP Launch Management Changes: Henry Ines to stay on in Emeritus role; Axel Schumacher to return as CEO

CEO

Shivom Ventures Limited announced today Henry Ines will restore Axel Schumacher as Chief Executive Officer and stay on as CEO Emeritus. Additionally, Shivom has tapped Nate Raine for the Chief Operation Officer role and for Meer Ali to become the Chief Technology Officer.

London, United Kingdom – 8th August – Shivom announced today that Henry Ines has decided to step down and restore Axel Schumacher as acting Chief Executive Officer of Shivom. Henry will stay on as CEO Emeritus acting in an advisory role for Shivom post-MVP platform release. It’s been a little over a year since Henry Ines stepped into the CEO role and during his tenure with Shivom, he has managed to take both founders vision and create a product which can massively disrupt the genomics industry. Additionally, Henry has brought countless partnerships and pilot projects to Shivom such as Lifebit, H2020, CC-TDI, Family Care Path and more. “It’s been a great honor to work closely with our global team to build a highly innovative clinical SaaS platform and consumer genomics marketplace, which combined we believe are poised to disrupt the clinical research, drug discovery and personalized healthcare spaces. I stepped up as CEO in 2018 to help the team focus on execution and to navigate through an especially difficult post-ICO period, when the project was not only at its infancy, but the broader crypto industry was also experiencing significant challenges. Twelve months later, we have persevered and now have a fully functional world-class patient-centric MVP product, unparalleled ‘3 clicks’ integrated bioinformatics analysis capability, dynamic consent & permissions via smart contracts, a blockchain-based immutable consent audit trail functionality, established multiple strategic and complementary partnerships globally, a consumer marketplace with curated ‘best of breed’ personalized care products, demonstrated OMX token utility via payments and gamification/rewards, and have commenced with onboarding of initial customers, pilots, and monetization via our established business model. With these and many other accomplishments, I felt post MVP launch was the appropriate juncture for me to step down for new leadership to guide the next phase of the project. I have full confidence in the team and the excellent trio of Axel, Nate, and Meer, whom collectively have more than 50+ years of diverse operational, clinical, technical and startup experiences to take the business to the next level,” said Henry Ines, CEO Emeritus.

Axel Schumacher has led the Science and R&D team for the past year since Henry Ines took over his previous position. During his tenure as CSO, he was responsible for integrating bioinformatics partners and championing solutions for pilot projects ranging from Children’s Cancer to Medicinal Cannabis. Axel has an excellent track record with leading pharmaceutical companies and research organizations globally. He will return to his previous position and help the company scale and steer Shivom forward into the genomic landscape by utilizing his impressive 30+ years of experience working in the industry.”As we enter into this next critical stage, I am thrilled to lead the team, focusing on tackling the many problems associated with the global healthcare system through genomics. Returning as CEO, I will utilize my industry knowledge with pharma and make sure the team continues on the trajectory Henry has worked so hard to put us on. We are looking forward to being able to empower researchers by providing them with the tools to discover much deeper insights in half the time traditional analysis would take. Additionally, enabling individuals to better manage their health and wellness through Shivom’s secure blockchain-based technology platform and healthcare ecosystem,” said Axel Schumacher, Chief Executive Officer.

Lastly, Nate Raine has been tapped for the Chief Operating Officer (COO) role and lead operations out of Shivom’s London head office. Leveraging his deep background in startup operations, business development and scaling various solutions for enterprise organizations, Shivom will be poised for significant growth in the coming year. Meer Ali has also been elevated to the role of Chief Technology Officer (CTO). With his 20+ years of deep technical experiences, Meer will continue to oversee and lead Shivom’s product development efforts, while helping to grow the company’s technical team and footprint globally. The management team and advisors believe these roles reflect the most direct path to success for a post-platform released Shivom.

A successor to the role of Director, Marketing & Communications will be announced shortly. The team is thankful for the continued support of its partners, investors, and community.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data discovery and analysis company optimizing the way DNA is shared, secured and analyzed. By utilizing innovative technologies such as blockchain and machine-learning algorithms, we are able to democratize genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratization of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

Recommended

Clinical SaaS

Shivom Releases MVP; Offering Clinical SaaS-based Automated Data Analytics

Clinical SaaS

Shivom Ventures Limited releases its MVP which provides researchers with a Clinical SaaS-based platform to search for datasets and run genomic pipelines in three clicks of the mouse. 

London, United Kingdom – July 29, 2019 – Shivom, a biotechnology data discovery and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has released it’s long-awaited MVP. This release seeks to target data owners who are not only looking to securely store their DNA and other biodata but enable them to monetise their data within the research community. Through a combination of explicit consent mechanisms, blockchain and smart contract technology, data owners are provided traceability and complete control over their data.

The release will be made live to the public at 2:00 pm GMT on 29th July. This is a major milestone for Shivom, the company will now offer researchers the ability to search for datasets and run genomic pipelines in three-clicks of the mouse under their new clinical SaaS-based solutions.

“In my 20 years of experience working in the field and within biobanks led to the automation of analysis for the researchers on our platform. Using Shivom’s Clinical SaaS platform can help organisations not only reduce the cost of R&D but make research easy and accessible. Were stripping away the pre-requisites other bioinformatics platforms require the researcher to possess in order to run pipelines and tools such as GWAS or SAM Tools. With access to patient biosamples and open data, time is finally freed for the researchers who currently have to scour and prep data for analysis,” said Dr Darrol Baker, Head of Bioinformatics.

Shivom’s clinical SaaS solution will seek to solve pharma’s most hard-hitting challenges, lack of innovation in bioinformatics, increasing R&D costs and siloed data. These challenges have been solved through a unique approach by utilising the best in breed technologies at our disposal. “Utilising new innovative smart contract solutions are at the heart of the Shivom Platform to enable user consent and monetisation. Cloud-native bioinformatics analysis solutions to ensure data is always with Shivom and processing is lightning fast. Smart coding techniques for smarter smart contracts enabling storage of large amounts of data at a fraction of the gas cost. Innovative integration with Ethereum so that the user does not have to pay GAS cost to use smart contracts. Never before seen use cases for data owners to use their data as well as discover and use data on our platform. A platform for modern genomics,” said Meer Ali, Director of Technology.

Alongside updated permissions and an end-to-end solution for researchers, the MVP contains major updates to the consumer shop; offering additional 6 products, new UI and provides consumers with the choice of purchasing via OMX tokens or cash. One of the products Shivom will be offering for purchase is a DNA test which analyzes the 11 genes that are responsible for your skin’s hydration, elasticity, photoaging, and skin antioxidant protection, created by using the knowledge of modern genetics in skincare. By taking the DNA test you will receive a personalised report, which will provide you with general skincare recommendations which are important for your specific genotype. Another product that will be introduced is Strain Genie’s Cannabis DNA kit, which provides consumers with personalized insights and important warnings about how your body may or may not respond to specific cannabinoids, terpenes and strains of Cannabis.

“I’m incredibly proud of the team and their hard work and commitment to deliver on this critical milestone. With our MVP, enterprises and researchers have the ability to search and discover diverse datasets globally, enter into smart contracts with data owners and utilize our integrated, streamlined bioinformatics analysis and reporting features, while also benefiting from our blockchain-enabled audit and patient consent functionalities for compliance purposes. These innovative solutions represent a new paradigm for robust multi-omics analysis, which we anticipate will result in significant clinical efficiencies and ultimately the accelerated delivery of personalized care and therapies.” said Henry Ines, CEO of Shivom.

Following the MVP release, Shivom will focus its efforts on not only improving the customer experience but adding pipelines, support for other bioinformatic providers, enhanced reporting features and additional security layers to the Clinical Saas-based solution.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data discovery and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

Recommended

Hepatoblastoma

Shivom and cc-TDI to Advance Clinical Research for Hepatoblastoma & Other Rare Pediatric Diseases

Hepatoblastoma

Shivom Ventures Limited (“Shivom”) and Children’s Cancer Therapy Development Institute (“cc-TDI”) enter into a Memorandum of Understanding (MOU) to explore a partnership for advancing clinical research and drug discovery for rare pediatric genetic diseases.

LONDON and PORTLAND – July 10, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has signed an MOU with cc-TDI, a unique non-profit organization focused on the ‘preclinical gap’ in childhood cancer research. The two entities will explore a partnership empower families with precision medicine solutions and community-driven data sharing for children suffering from Hepatoblastoma Tumors.  This approach is the next evolutionary step of the “It’s my Data” movement that makes patients into citizen-scientists (https://www.wsj.com/articles/SB10001424052970204621904577014330551132036).

Through this MOU, Shivom will utilize their AI and Blockchain powered patient recruitment platform and dynamic permissions & consent features to help cc-TDI to develop preclinical and eventual clinical solutions to combat this rare disease. Hepatoblastoma is a very rare cancerous tumour that starts in the liver. This disease primarily affects children from infancy to approximately 3 years of age. To date, developing a cure or new therapies is increasingly difficult because of the lack of Hepatoblastoma Genomes sequenced, partly pertaining to how extremely rare these genomes are and the subject matter of sequencing DNA from children below the ages 5. Shivom will leverage its global affiliate network and innovative clinical research & recruitment platform to help break these barriers in order to bring awareness and help make parents and legal guardians full partners in research for cures. “Shivom is proud to support cc-TDI with its critically important drug development research work to include tackling rare pediatric diseases such as hepatoblastoma, the most common primary liver tumor diagnosed in childhood. We plan to leverage our unique technology solutions and global recruitment platform to drive awareness and ultimately aim to secure the additional datasets and tissue samples needed to advance clinical research and expedite the delivery of a cure for hepatoblastoma and other rare genetic diseases afflicting children globally.” said Henry Ines, Chief Executive Office of Shivom.

To date, cc-TDI and its colleagues worldwide have collected less than 150 children’s hepatoblastoma tumours to determine DNA mutations and RNA-based gene expression. This is significantly low; researchers need more information in order to better understand the full range of mutations in this cancer. “Hepatoblastoma can have an outstanding outcome if surgery can remove the tumor, yet for those with refractory, metastatic or relapsed disease – the options are few.  The number of drug targets carefully explored for these desperate patients over ten years is less than a half-dozen, and primarily because so few datasets exist for patients with advanced disease.  The voucher system to be offered by Shivom, and the way in which the Shivom platform puts patients in control of data sharing represents a cultural shift in the precision medicine and the search for hepatoblastoma cures.”

About Shivom
Shivom is a biotechnology and precision medicine company optimising the way healthcare data is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to drive clinical efficiencies and democratise genomics.

Our mission is to bring exponential value to our end-users within the global genetics and precision medicine ecosystem. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here
Learn more about our genetic counselling pilot here
Learn more about the TranSYS grant here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Children’s Cancer Therapy Development Institute
The Children’s Cancer Therapy Development Institute (cc-TDI, www.cc-tdi.org) is a unique non-profit organization focused on the ‘preclinical gap’ in childhood cancer research. Our mission is to bridge scientific discovery and the initiation of clinical trials. Through our efforts, we will provide evidence-based testing for the selection of new drugs to be used in childhood cancer clinical trials, thus seeding pediatric Phase I and II trials. This concept was emphasized in the Institute of Medicine Report, Making Better Drugs for Children with Cancer in 2005. Our longstanding work with mouse models of brain tumors and sarcomas is the cornerstone for basic science & target discovery and our mission. The cc-TDI research team is led by Scientific Director Dr. Charles Keller who follows in the footsteps of his mentor, 2007 Nobel laureate Mario Capecchi. The cc-TDI laboratory is based on the premise of a non-profit multidisciplinary biotech and is thus located in between the Silicon Forest in Beaverton, OR (Intel Headquarters) and the Portland-area medical center. Our industrial-modern 4600 ft2 BSL wet lab facility is a former 70-year old paint factory remodeled by Nike as an off-site creative space – an ideal setting to spark innovation.

Recommended

genetic counselling

Shivom and Family Care Path Launch Genetic Counselling Pilot

genetic counselling

Shivom Ventures Limited and Family Care Path have launched a Genetic Counselling Pilot in order to help patients from the United States have a deeper understanding of their genetic information through testing, counselling and the ties to family health history

London, United Kingdom and Cleveland, Ohio – July 1st, 2019 – Shivom Ventures Limited (“Shivom”), a biotechnology data and analysis company optimizing the way DNA is shared, secured and analyzed through blockchain and AI technology, and Family Care Path (FCP), a spin-off company from Cleveland Clinic, adapting and marketing web-based clinical decision support applications, have launched a telemedicine genetic counselling pilot today.

Shivom and Family Care Path will offer patients who have a family history of Cancer, Diabetes and or Cardiovascular issues genetic counselling sessions through CarePathConnect. These sessions will be available to purchase from Shivom’s shop for 1,000 tokens later next month. Following purchase, customers will be redirected to FCP’s MyLegacy application where they will be asked to fill out a unique health questionnaire. After the questionnaire has been completed, the patients will receive a Risk Assessment Report; this report will provide patients with an overview of their risk of inheriting certain genetic conditions. Once the patient has received their Risk Assessment Report they will be able to schedule a genetic counselling session with one of Family Care Path’s Genetic Counsellors. The pilot will only be available to patients who are living within the United States at this time.

 “We are excited to partner with the unique offerings of Shivom to provide individuals with powerful information to understand their family health history tied to genetic and hereditary risks. Our genetic risk tool, MyLegacy, combined with the support of genetic counselors provides expanded depth to the blockchain and AI capabilities of Shivom. We are confident this dynamic information will be insightful and beneficial to the end-users and their physicians,” said David McKee, CEO and President of Family Care Path.

 “For those who may be predisposed to or have a family history of cancer, diabetes or heart disease, undergoing genomic sequencing to gain additional insights may prove to be invaluable,” said Henry Ines, Chief Executive Officer of Shivom. “That said, interpreting sequencing results and understanding the appropriate therapeutic course of action may be challenging without the proper guidance from genomic counsellors. Accordingly, we are thrilled to work with Family Care Path, which maintains a network of certified, licensed clinical genetic counselors, who through the use of FCP’s proprietary risk assessment tools and its HIPAA compliant video telemedicine platform are able to help patients on a variety of critical matters ranging from better understanding potential risks associated with certain hereditary conditions, managing their health & wellness, mitigating against health risks to assessing the need for ordering additional genetic tests. We are excited to offer these additional resources to our customers in the US; eventually globally.”

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimizing the way DNA is shared, secured and analyzed. By utilizing innovative technologies such as blockchain and machine-learning algorithms, we are able to democratize genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratization of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Family Care Path
Family Care Path develops, adapts and markets web-based clinical software applications designed to improve patient outcomes, increase physician and clinical process efficiency, and interface with a variety of electronic health records.

Many exciting concepts for healthcare applications remain isolated within the development environment. Our company’s mission is to identify these opportunities and develop software solutions utilizing industry standard protocols, to enable widespread adoption.

We utilize the latest technology to develop secure and scalable applications to improve the quality of healthcare and reduce cost. Leveraging industry standard technologies such as Microsoft Cloud and both the SMART® and HL7® FHIR® open standards, Family Care Path creates applications which can seamlessly communicate with all electronic health record systems.

For more information about Family Care Path please visit:

www.familycarepath.com

Recommended

horizon 20/20

Shivom Joins Consortia on Horizon 20/20 TranSYS €EUR4 Million Grant

horizon 20/20

Shivom joins European consortia of clinical and innovative tech organisations on Horizon 20/20 TranSYS Programme. The 4 Million Grant will be used to fund 15 Early Stage Research (“ESR”) projects.

London, United Kingdom – June 27, 2019 – Shivom Ventures Limited (“Shivom”), a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, joins European consortium of clinical and innovative tech organisations on Horizon 20/20 TranSYS Programme. The EUR4 Million Grant will be used to fund 15 Early Stage Research (“ESR”) projects seeking to advance and improve diagnostics, disease risk and treatment management, clinical sampling and more targeted therapeutic areas.

TranSYS research projects focus on “Integrating Big Data and ICT Solutions” and “Translating Basic to Clinical Research”. These areas are highlighted in the International Consortium for Personalised Medicine (ICPerMed) 2017 Action Plan4 as key challenges to develop new diagnostics, treatments, and healthcare approaches, to benefit European citizens and society. Part of the funds from the grant will be set aside for Shivom to work with each of these ESR’s to implement Shivom’s blockchain and AI-powered solutions all the while developing their own clinical research programme focusing on methylation events within Cancer and sports medicine. Shivom was picked for this project in particular because of their strong use case for data compliance and patient confidentiality. Additionally, the Horizon 20/20 programme will allow for recruiting a Clinical AI PhD student which will be supervised by Dr Darrol Baker.

“The molecular identification, characterization and secure patient consent for data use is a key measure within the realms of precision medicine and the prevention of ‘walling’ of genotypic and phenotypic data globally,” said Dr Darrol Baker, Head of Bioinformatics for Shivom. “Existing data in today’s digital universe offer tremendous opportunities to achieve this but for extracting insights and information from multiple heterogeneous and interdependent data in precision medicine, requires new systems analytics, moving beyond classical AI,  algorithmic or mechanical processes and validation against disease models. The Horizon 20/20 TranSYS research projects focus on Integrating Big Data and ICT Solutions and Translating Basic to Clinical Research. Shivom’s clinical blockchain AI solutions and the TranSys programme offer a unique 4-year window to explore and innovate global blockchain precision medicine.”

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Horizon 20/20
Horizon 2020 is the financial instrument implementing the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe’s global competitiveness.

Seen as a means to drive economic growth and create jobs, Horizon 2020 has the political backing of Europe’s leaders and the Members of the European Parliament. They agreed that research is an investment in our future and so put it at the heart of the EU’s blueprint for smart, sustainable and inclusive growth and jobs.

By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.

Horizon 2020 is open to everyone, with a simple structure that reduces red tape and time so participants can focus on what is really important. This approach makes sure new projects get off the ground quickly – and achieve results faster.

The EU Framework Programme for Research and Innovation will be complemented by further measures to complete and further develop the European Research Area. These measures will aim at breaking down barriers to create a genuine single market for knowledge, research and innovation.

For more information about Horizon 20/20  and it’s research programmes please visit https://ec.europa.eu/programmes/horizon2020/en

Recommended

Cannabis

Shivom and TruTrace Technologies to Explore Clinical Solutions for Cannabis Market

Cannabis

Shivom Ventures Limited and TruTrace Technologies Inc. will explore a partnership to utilize both Shivom and TruTrace’s blockchain solutions in order to disrupt the global medicinal and recreational cannabis markets.CanabbisLONDON and TORONTO – June 25, 2019 – Shivom Ventures Limited (“Shivom”), a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, and TruTrace Technologies Inc. (CSE: TTT; OTC: TTTSF) (“TruTrace” or the “Company”), which has developed the first integrated blockchain platform that registers and tracks intellectual property for the cannabis industry, announced that the two companies have signed a letter of intent (“LOI”) to establish a strategic working relationship. The companies will explore a partnership to utilize both Shivom and TruTrace’s blockchain solutions in order to disrupt the global medicinal and recreational cannabis markets

Through the LOI, Shivom is entering into the booming cannabis market, which is projected to hit US$40 billion by 2024 – nearly triple the US$14.9 billion estimated to be spent this year, according to ArcView Market Research and cannabis industry analysis firm BDS Analytics.

“Shivom is excited to enter the cannabis market via a strategic partnership with TruTrace, which has developed the first integrated blockchain platform to register and track IP in the cannabis industry,” said Shivom CEO, Henry Ines. “As the industry is still in its early stages in terms of understanding and uncovering all of the medicinal benefits associated with the use of CBD, Shivom is keen to work with leading organizations in the space such as TruTrace to further uncover additional therapeutic benefits based on one’s genomic profile and unique personal health information. Shivom anticipates significant opportunities to collaborate with TruTrace and its partners to provide clinical research opportunities, medical insights and personalized healthcare products to consumers and patients within the global cannabis ecosystem.”

“Shivom has developed some very interesting technology that combines genomics, cryptography and AI, and we are excited to begin collaborating with them,” said TruTrace CEO, Robert Galarza. “We plan to explore development and integration opportunities to advance clinical research, and bring greater transparency, insights and viability to the legal medical and recreational cannabis industry.”

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:

Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About TruTrace Technologies

TruTrace Technologies has developed the first integrated blockchain platform to register and track intellectual property in the cannabis industry. TruTrace’s technology allows cannabis growers and breeders to identify and secure rights to their intellectual property. It also streamlines the administrative process and reduces the costs of genetic and mandatory quality-control testing for legal cannabis. TruTrace’s technology is proprietary, immutable and cryptographically secure, thereby establishing an accurate and permanent account for cannabis strains from ownership to market.

For more information about TruTrace Technologies please visit https://strainsecure.com/.

For More Information:

TruTrace Technologies Inc:
Robert Galarza, Chief Executive Officer and Director; Media Relations: Lori Harito, RNMKR Agency, 416-523-9602, lori@rnmkr.agency; Investor Inquiries: Swapan Kakumanu, Chief Financial Officer, 403-681-2549, swapan@trutrace.co

Disclaimer for Forward-Looking Information
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company, including the statements regarding: the expected synergies between TruTrace and Shivom; the expected benefits to the Company of the proposed relationship with Shivom; the expected date of entry into the Formal Agreement and conditions of closing to the transactions contemplated thereby; and that the Company and Shivom will successfully develop a solution that has a disruptive affect on the global recreational and medicinal cannabis industry. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forward-looking information necessarily involves known and unknown risks, including, without limitation, risks associated with general economic conditions; other parties involved in the Pilot Program; that sufficient numbers of researchers, clinicians, physicians, pharmacists, and patients will be available to participate in the Pilot Program; potential negative results of the Pilot Program; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States, and elsewhere; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry generally in Canada, the United States and elsewhere; and other risks. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information contained in this news release.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.

Recommended

Lympo

Shivom Partners with Lympo to Incentivise Fitness Goers

Lympo

Shivom in cooperation with Lympo will provide fitness goers token incentives when accomplishing daily fitness challenges and completing healthcare questionnaires this summer.

London, United Kingdom – May 23, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has partnered with Lympo, a free mobile app that allows you to earn money just for walking, running or even squatting. Complete these daily challenges, receive token rewards to be redeemed in-app for healthy lifestyle goods and services.

Through this partnership, Shivom and Lympo this summer will invite it’s users to complete select daily challenges via the Lympo app. This partnership is about conducting joint challenges which support each other’s respective ecosystems and missions centred around fitness, wellness and healthcare. The first co-branded challenge will be made available June 15th; asking users to complete a 4 km run and additionally sign up to Shivom’s platform and complete a health questionnaire in order to receive LYM and OMX tokens.

Shivom aims to onboard new customers onto Shivom’s platform, which provides customers with the ability to purchase DNA-based and other personalized healthcare products and services; to earn tokens via unique healthcare-related tasks and programs; and the opportunity to directly participate in and earn compensation if desired when providing data for clinical research. Shivom recently launched its ‘Shop 1.5’ — the first cut of Shivom’s consumer marketplace, which provides consumers with unique incentives and the ability to purchase direct-to-consumer genetic testing products either by OMX token or fiat payment. [hyperlink to press release].

The Lympo application is available for both iOS and Android and provides customers with a simple way to get rewarded for getting fit. Along with the incentives of data ownership, Lympo creates incentives through tokenized rewards. By participating in social challenges and documenting benchmarks, users can earn Lympo tokens, which they can exchange for products in the Lympo ecosystem. Jonušė, Chief Executive Officer of Lympo hopes this will have benefits at both a personal and a corporate level. Since the ICO, Lympo, has attracted 136,000 users, nearly 13,000 of whom are active daily, with over 1.6 million challenges completed. It’s already the number one fitness app in South Korea, and is partnering with major brands like Dallas Mavericks and Oxygen.

“We are thrilled to partner with Lympo to jointly sponsor daily fitness challenges and to offer token incentives via completion of select tasks on Lympo’s app and Shivom’s platform. Both organizations are focused on driving fitness and motivating individuals to make healthy lifestyle choices. There are considerable synergies as Lympo offers daily fitness challenges in a gamified manner while Shivom offers individualized healthcare products and services as well as the opportunity to monetize on the use of personal data for clinical research purposes. The partnership is also notable for the broader industry as two token projects converge for cross platform engagement and provide opportunities to earn and utilize both OMX and LYM native tokens — dynamics increasingly necessary for growing healthy token economies and ecosystems” according to Henry Ines, CEO of Shivom.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Lympo
Lympo is making the world healthier by rewarding people for exercising and leading healthier lives. With the help of blockchain technology and fitness gamification, users are rewarded with LYM tokens through the Lympo Run app, for completing walking and running challenges. These tokens can then be used to purchase quality sporting goods by top global brands in Lympo Shop – the first-ever online shop to accept fitness token payments.

We are actively building a complete data-sharing ecosystem, which in the future will connect fitness and wellness stakeholders (personal trainers, gyms, sports events, brands) with users via a blockchain based reward system, linked to users’ health and fitness data. We will also offer a place to collect, store and monetize this valuable data from a variety of health and fitness tracking apps or wearables.

Ultimately, the goal is to create a win-win situation for each platform participant – the users will be able to monetize their health and fitness data via the LYM utility token and the businesses, in return, will receive access to a tech-savvy community, passionate about healthy living.

For more information about Lympo please visit here

Recommended

Shivom

Shivom Releases Updated Marketplace, Enabling OMX Token Payment via MetaMask

Shivom

Shivom releases ‘Shop 1.5’ which provides consumers with unique incentives and the ability to purchase direct-to-consumer genetic testing products either by OMX token or fiat payment.

London, United Kingdom – May 23, 2019 – Shivom, a biotechnology data discovery and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has released its latest consumer marketplace ‘Shop 1.5’ along with additional updates to the user creation and login. This release will enable consumers with the ability to purchase genetic testings products either by OMX payment or fiat. Additionally, the team has made updates separating the login and creation for enterprise and consumer account and to the health and lifestyle questionnaire within the profile section.

The release will be live to the public at 12:00 pm GMT on 23rd May.  This is a major milestone for Shivom as it will not only enable consumers to purchase directly within Shivom’s marketplace via either OMX token or fiat payment but also bring mainstream partners to Shivom’s innovative blockchain eco-system.

The first group of partners featured on Shop 1.5 include Vitl, Living DNA and Chronomics, which provide ancestry, vitamin and cholesterol and epigenetic testing, respectively. Consumers purchasing any of these kits or services will need to agree to both Shivom and its partners’ terms of use and privacy policies.

At this time, customers are only able to purchase Chronomics epigenetic test with OMX tokens, whilst Living DNA and Vitl’s kits can be purchased with fiat via our partner’s checkout page. This allows users who don’t have tokens to be able to obtain their genetic data file and reports without having to buy tokens from an exchange. Customers who purchase with OMX tokens will receive an automatic email providing a voucher code.  This can then be redeemed on Chronomics website for one month’s subscription of EpiPlanner and a test kit. Please be aware, a minimum subscription of 12 months is required.

All of our D2C partners have undergone a thorough screening from our research and development (R&D) team prior to being granted promotional status within the marketplace. Shivom implements quality control procedures for its marketplace items and criteria which covers a variety of considerations to include data privacy, security and scientific quality (e.g., is a report evidence-based). When products or services are not supported by adequate clinical evidence, Shivom’s R&D team may request further evidence to support the potential partner’s case. Here is the link to our blog which provides an in-depth explanation of the reasoning we have for listing Vitl, Living DNA and Chronomics on our marketplace.

To mark this major milestone, for a limited time only Shivom is offering several exciting promotions. Customers who purchase either LivingDNA or Vitl kits and upload their data on Shivom’s platform will earn OMX tokens and also be eligible to receive special discounts or rewards on select products or services offered by Shivom and its partners (to be separately announced).

Additionally, for a limited time, only customers are also able to purchase Chronomics EpiPlanner Test Kit + 1 Month Subscription for only 1,000 OMX! That’s right, you read that correctly; for ~ $1 USD you can get your hands on this kit. Don’t miss out on this incredible opportunity!

“Today’s Shop 1.5 release stems from the collective hard work, focus and diligent efforts of our tech, science and business teams over the past 12 months. This release provides our early supporters with the ability to earn rewards for participating in our blockchain-based ecosystem and utilize either OMX tokens or fiat to procure top of the line kits from our curated product offerings. Once on our platform, consumers will not only have control over their data and be able to gain considerable health and wellness insights but also have the ability to participate in clinical research and even monetize on personal data if desired. We’re proud of early progress and also look forward to our upcoming MVP release, which will mark another significant milestone and showcase the first cut of our enterprise solution offerings and clinical functionalities.” said Henry Ines, CEO of Shivom.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data discovery and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

Recommended

Shivom

Here’s How Shivom Chooses it’s Marketplace Partners

Shivom

This week, Shivom will launch its first iteration of our direct-to-consumer health management marketplace.  In this post, we will be providing information to the community and prospective partners about how we determine which products and companies are listed on our platform.

Shivom’s mission is to not only optimize how DNA is shared, secured and analysed but to bring exponential value to our end-users. With this mission comes the responsibility to make some pretty tough decisions through and through. One of these decisions is choosing which companies Shivom would want to interact with within our eco-system. When our team started working on ‘Shop 1.5’ Shivom understood that we shouldn’t strive to be just a marketplace promoting every type of genetic testing product we could get our hands on. This business model not only has problems with scalability but additionally lowers the quality or value we bring to our audience. For these reasons and many more, our team developed quality control and criteria which are used to decide which partners should be able to gain entry to the marketplace.

The first part of our review is about companies’ data privacy and security policies. The first question we ask is, do you share data with third-parties? The second question we ask is, do you sell or utilise the user’s data in order to generate revenue? If the answer is yes to either one of these questions, straight off the back the company would be eliminated from being able to join our marketplace.

In the second part of the review, our team will determine the quality of the report and determine whether it brings any value or if it is B*** S***. A Great example of this is when I recently saw on a competitor’s website that they were sequencing a user’s DNA in order to find out what kind of t-shirt looked best on them (v-neck or crew).

The third part of our review is whether the product and or company brings value to the eco-system. For example, if someone recently purchased Living DNA’s 3-in-1 Ancestry Kit they might also be interested in learning about their nutrition and cholesterol. Instead of having to purchase an entire kit we look at products which allow people to use their Raw Genetic data gained from the Ancestry KIt instead of having to re-swab, prick or take a faecal sample all over again. Additionally, we are also looking at which products are complementary to each other and could go hand-in-hand

In case you were wondering what the reasons were for choosing Vitl, Living DNA and Chronomics for our first iteration, I’ve included below an in-depth explanation.

Vitl
Vitl products not only have a high rate of positive customer feedback (e.g. 91% of customers rated Vitl products as ‘Excellent’ on Trustpilot), the team is comprised
of experts in their field; such as geneticists, nutritionists who understand the science and the practical aspects of healthy nutrition. Vitl uses the latest innovative technologies, such as; artificial intelligence. Additionally, the company uses credible vendors and laboratories for their tests(e.g. UKAS-accredited and CQC-registered blood testing facilities) as well as Illumina CSPro Certified Service Providers in Europe and the USA for DNA testing. Whilst other brands may test for a larger number of less well-researched traits, Vitl emphasizes quality over quantity. They only cover traits based on the strongest, peer-reviewed evidence to ensure users are getting the most reliable results.

Lastly, similar to Shivom’s philosophy of combining different omics technologies to gain insight, Vitl enables the integration of DNA data alongside blood and dietary results and lifestyle information. This is important because supplement recommendations or lifestyle advice cannot be made on DNA information alone, but taken alongside current blood vitamin levels and diet that are measured in a longitudinal way.

Living DNA
Living DNA launched back in 2016 as a collaboration of more than 100 scientists, researchers and genetic experts. We added Living DNA as a partner to our ecosystem because they provide precise ethnic estimates of ancestry testing. The 3-in-1 test covers the biggest number of genetic populations, which translates to the most accurate genetic percentages and offers unrivalled worldwide regional and sub-regional detail. The test incorporates three separate tests in one, giving the customer more for their money than any other ancestry tests on the market right now.

Additionally, instead of just getting your basic family ancestry (autosomal DNA), you also get an analysis along your mother line (derived from mitochondrial DNA) and your father line (derived from the male-specific y-chromosome). Living DNA is a holder of ISO:27001 certification, which demonstrates good protection and security for personal and genetic data. As DNA samples are only connected to unique ID numbers, not even its staff members will know the identity of its users. The company works with “Show Racism the Red Card,” a group that fights racism to provide a safe space to reduce racist ideas and attitudes. Lastly, Living DNA provides the raw data of all test results which can be used on the Shivom precision medicine platform to foster research and fight rare diseases.

Chronomics
Epigenetic testing is relatively new to the direct-to-consumer testing market. We partnered with Chronomics because of their impeccable experience in this field. Our CSO, Dr Axel Schumacher is one of the many pioneers of epigenetics and worked alongside some of the Chronomics team members.

Epigenetics is the study of changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself. Epigenetic testing offers additional value to genomic testing, in particular, allowing individuals to analyse how environmental and lifestyle choices affect the body and how these patterns change over time. By monitoring epigenetic patterns, it is possible to collect actionable insight allowing for a personalized improvement plan. Most importantly, Chronomics provides users with the ability to gain access to their raw data which can be managed, stored and monetized on Shivom.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here
To read more about our affiliation with Chronomics please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

Recommended

Epigenetic

Shivom Adds Chronomics to the Marketplace, Offering Customers Epigenetic Testing with OMX Token Payment

Epigenetic

Chronomics EpiPlanner Epigenetic Test will provide Shivom’s customers with lifestyle and environment indicators to reveal an overall picture of your health.

London, United Kingdom – May 20, 2019 – Shivom, a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed through blockchain and AI technology, has teamed up with Chronomics, an online health services company which helps you understand how your environment and lifestyle choices are impacting your body and mind at the level of your DNA; to offer Chronomics EpiPlanner Epigenetic Test within Shivom’s marketplace. Through this affiliation, Shivom’s customers can discover lifestyle and environment indicators to reveal an overall picture of your health.

Epigenetic

Through a simple saliva test kit, the test will measure an epigenetic marker called DNA methylation, which can shift with environment and lifestyle. Customers who get the kit can log onto a web portal to find out their “biological age” — a well-established metric built on research by Chronomics in-house scientists. Scientists refer to biological age as to how old a person seems. Currently, the most accurate way to measure biological age is with epigenetics. This means that your age is NOT just a number. Your age is whatever you choose to make it.

For a limited period of time, Shivom plans to offer customers who sign up for Chronomics’ services or purchase other newly listed DNA products on Shivom’s marketplace with unique incentives ranging from token rewards to discounted reports and genetic counselling sessions via Shivom partners and affiliates. “In addition to recently added Living DNA ancestry and Vitl’s Vitamin and Cholesterol Blood Test Kit, we are now also pleased to offer Chronomics’ pioneering Epigenetic Test Kit, which will provide our customers with insights on their metabolic state, biological age and overall health as a result of diet / lifestyle choices and exposure to pollution. Notably, as the first consumer testing kit of its kind, Chronomics’ Epigenetics kit will also be able to be procured via OMX tokens. This is a very exciting development not only for our ecosystem but also for the broader blockchain & crypto industry.” Says Henry Ines, CEO of Shivom.

For more information about Shivom please visit here
To read more about our affiliation with Living DNA please visit here
To read more about our affiliation with Vitl please visit here

About Shivom
Shivom is a biotechnology data and analysis company optimising the way DNA is shared, secured and analysed. By utilising innovative technologies such as blockchain and machine-learning algorithms, we are able to democratise genomics.

Our mission is to bring exponential value to our end-users within the genomics industry. We believe that the unique combination of our in-depth knowledge for genomics, mixed with deep-rooted backgrounds in cryptography and AI is essential in the democratisation of genomics and healthcare data.

Learn more about our direct-to-consumer solutions here

Shivom Social Channels:
Official Homepage: shivom.io
Twitter (English): @projectshivom
Youtube: Shivom’s Channel
Telegram: Shivom Announcements
Facebook: @projectshivom
Instagram: @projectshivom
Medium: Shivom Official
LinkedIn: @projectshivom

About Chronomics
Chronomics has built an online digital platform that uses epigenetics to give people the knowledge of how their environment and lifestyle is imprinting itself on their DNA and affecting their health. From a simple saliva test, users have access to the knowledge of how their environment and lifestyle is affecting them. Combined with the power to enact change through user recommendations to enable them to live healthier and happier for longer.

#HackYourDNA with Chronomics

For more information about Chronomics please visit here

Recommended